Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib plus intensive chemotherapy in newly diagnosed NPM1-mutated acute myeloid leukemia
2021-000761-33Phase 3Terminated
- Sponsor
- Kronos Bio, Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Entospletinib plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: MRD-negative complete response rate. Started Aug 2021; status: terminated.
02
Drugs
entospletinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-000761-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000761-33.